Clinical-stage, AI-native biopharma using a proprietary biology-first machine-learning platform to analyze human disease and genomic data, discover therapeutics, and identify patient subpopulations most likely to respond
Clinical-stage, AI-native biopharma using a proprietary biology-first machine-learning platform to analyze human disease and genomic data, discover therapeutics, and identify patient subpopulations most likely to respond. Its pipeline includes cancer therapies such as AU-409 for liver cancer, as well as programs related to prostate cancer and chemotherapy-associated heart protection.